Document Detail

Treatment of diastolic dysfunction in hypertension.
MedLine Citation:
PMID:  22743209     Owner:  NLM     Status:  Publisher    
Diastolic dysfunction is present in half of patients with hypertension and has been shown to be associated with increased cardiovascular morbidity and mortality, as well as the development of heart failure. With the high prevalence of hypertension and its associated complications, treatment of diastolic dysfunction in hypertension is an important and desirable goal. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have been shown to be effective in improvement of measures of diastolic function and are recommended as first-line agents in the control of hypertension in patients with diastolic heart failure. Beta-blockers, calcium channel blockers, and diuretics have also shown some efficacy in improved indices of diastolic filling. However, the independent impact of these pharmacologic interventions on prognosis and outcome in diastolic dysfunction has yet to be clarified. The Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) study, Candesartan in Heart Failure: Assessment in Reduction of Mortality and Morbidity (CHARM-Preserved) trial and the Losartan Intervention For End-point Reduction in Hypertension (LIFE) Study all failed to show improved morbidity and mortality with these drugs although, the LIFE study showed reduced heart failure hospitalization in hypertensive patients with normal in-treatment diastolic function. The Trial Of Preserved Cardiac function heart failure with an Aldosterone anTagonist (TOPCAT) is an on-going large, international study evaluating the effect of spironolactone on cardiovascular mortality, aborted cardiac arrest, or hospitalization for diastolic heart failure. This and other studies will provide further insight into the pathophysiology and management of patients with diastolic dysfunction.
P Ginelli; J N Bella
Related Documents :
8996629 - Ischaemic preconditioning protects against myocardial dysfunction caused by ischaemia i...
1913749 - Reduced prostaglandin release from the stunned porcine heart--significance for attenuat...
2308369 - L-aspartate improves the functional recovery of explanted hearts stored in st. thomas' ...
10930819 - Fk409 ameliorates ischemia-reperfusion injury in heart transplantation following 12-hou...
18973759 - Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an is...
16557469 - Antiarrhythmogenic and antioxidant effect of the flavonoid dioclein in a model of cardi...
18346649 - Is beta-thalassemia trait a protective factor against ischemic cerebrovascular accidents?
10720599 - Overweight and hypertension : a 2-way street?
6789729 - Oxygen delivery in acute exacerbation of chronic obstructive pulmonary disease. effects...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-26
Journal Detail:
Title:  Nutrition, metabolism, and cardiovascular diseases : NMCD     Volume:  -     ISSN:  1590-3729     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111474     Medline TA:  Nutr Metab Cardiovasc Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier B.V. All rights reserved.
From the Department of Medicine, Bronx-Lebanon Hospital Center and Albert Einstein College of Medicine, Bronx, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment of subacute and chronic thrombotic occlusions of lower extremity peripheral arteries with ...
Next Document:  Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study.